eSense-Lab

Company Overview

Snapshot

Founded in April 2016, eSense-Lab operates with 1–10 employees. The company has raised $2.48 million across one funding round. A significant milestone for the company was its debut on the ASX in February 2017.

Business overview

eSense-Lab is a pharmatech company focused on re-engineering the chemical composition of plants, primarily cannabis, for commercial applications. The company utilizes advanced technologies to reverse-engineer chemical profiles of rare or lucrative plants, then reconstructs them using alternate natural products to create virtual plant formulations. This process yields plant-based products with commercial and medicinal uses, targeting multiple markets and mass consumer consumption within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Medical Cannabis.

Strategic signal

In April 2023, eSense-Lab ceased operations, indicating a significant shift in its business trajectory and market presence. This cessation of activity suggests a challenging period for the company, impacting its ability to continue its work in re-engineering plant chemical compositions for commercial and medicinal applications.

Company Intelligence Q&A

What is eSense-Lab's primary focus?

eSense-Lab specializes in reverse-engineering the chemical composition of plants, particularly cannabis, to reformulate them for commercial and medicinal applications.

When did eSense-Lab debut on the ASX?

eSense-Lab debuted on the ASX in February 2017.

What was a key commercial agreement for eSense-Lab in 2018?

In October 2018, eSense-Lab signed a two-year commercial supply agreement with E-Quits Group.

What was a significant leadership change for eSense-Lab?

In March 2020, eSense-Lab appointed Itzik Mizrahi as its CEO.

What was the outcome for eSense-Lab in April 2023?

In April 2023, eSense-Lab ceased to operate, leading to its non-active status.